Daprodustat: First Approval
Any type of resource available online.
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest S. Dhillon is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conficts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here
(Duvroq) is a small molecule inhibitor of hypoxia-inducible factor prolyl
hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of anaemia in
patients with chronic kidney disease (CKD). Inhibition of PHD prevents
degradation of hypoxia-inducible factor (HIF), leading to the production of
erythropoietin and subsequent induction of erythropoiesis. In June, daprodustat
received its first approval in Japan for the treatment of renal anaemia. Clinical studies of
daprodustat are underway in multiple countries worldwide. This article
summarizes the milestones in the development of daprodustat leading to this
first approval for the treatment of renal anaemia.
© Springer Nature Switzerland AG 2020